Poland dispensed roughly 5,450 kilograms of medical cannabis flower through its pharmacies in 2025, about 12 percent more than the year before, and every gram of it was imported. The country has no commercial domestic cultivation, which makes it one of the few European markets where a Canadian Licensed Producer competes on product and paperwork alone rather than against local growers.
Exporting cannabis to Poland in 2026 requires three things working together. First, a Health Canada export permit for each shipment under the Cannabis Act. Second, an EU-GMP release path, almost always through a European partner site, because Poland accepts only EU-GMP product. Third, a Polish partner that holds a URPL marketing authorisation for your specific flower plus GIF import permits.
This guide walks through how the Polish system works, what you need in place before a first shipment, what the market data says, and where Canadian LPs typically lose time.
How Poland's medical cannabis import system works in 2026
Poland legalised medical cannabis on 1 November 2017 through an amendment to its Act on Counteracting Drug Addiction of 29 July 2005. The model it chose is unusual. Dried flower is classified as a pharmaceutical raw material, not a finished medicine, and pharmacies compound it into individual preparations against a prescription. There is no statutory list of qualifying conditions, and any licensed physician can prescribe.
Two regulators control access. The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) grants the marketing authorisation for each raw material product. That authorisation is valid for five years and, according to Prohibition Partners' 2025 market overview, typically takes up to two years to obtain. The Chief Pharmaceutical Inspectorate (GIF) licenses the wholesalers and importers, issues the narcotics authorisation they need to handle cannabis, and approves imports on a per-shipment basis.
Cultivation is effectively closed. Only research institutions can grow cannabis under a special GIF permit, and only one entity has ever received one. That is why Business of Cannabis reported in April 2026 that roughly 68 percent of Polish flower originates in Portugal and about 32 percent in Canada, with most product packaged in Germany before it crosses into Poland. If you've read our guide to the two-permit chain for cannabis imports, the Polish structure will look familiar, with one difference: the product itself must be authorised before any permit is issued.
Poland versus Germany at a glance
| Element | Poland | Germany |
|---|---|---|
| Product status | Pharmaceutical raw material, pharmacy-compounded | Medicinal product under the MedCanG |
| Product authorisation | URPL marketing authorisation, 5-year validity | No product-level authorisation for flower |
| Import permits | GIF, per shipment | BfArM, per shipment |
| Domestic cultivation | None commercial | Limited, import-reliant |
| Quality standard | EU-GMP release required | EU-GMP release required |
What Canadian LPs need before a first Polish shipment
The Polish side of the chain is only half the work. Your own export authorisation, testing, and quality release have to line up with it, and the order matters. Here is the sequence we recommend.
The Poland Entry Path: 5 steps
- Confirm your export eligibility in Canada. You need a Health Canada licence that permits sale, and each shipment needs its own export permit under the Cannabis Regulations. Exports are limited to medical and scientific purposes, and the destination importer's permit must be in hand before Health Canada will issue yours. Our step-by-step guide to the Health Canada export permit covers the application in detail.
- Secure an EU-GMP release route. Polish pharmacies can only dispense EU-GMP product. If your Canadian site isn't EU-GMP certified, your flower ships as GACP starting material to a certified European site, where a Qualified Person tests, packages, and releases it. Most Canadian flower entering Poland today takes this route through Germany. Read how EU QP batch release works for Canadian LPs before you negotiate the partnership.
- Choose a Polish partner that already holds or will file the URPL authorisation. The authorisation is product-specific and names the cultivar, potency range, and manufacturer. Given the two-year timeline, a partner with an existing authorisation that your flower can fit under is the fastest entry. A new filing means planning revenue two years out.
- Align your certificate of analysis with the Polish specification. The URPL authorisation fixes a THC and CBD range. Every batch must land inside it, verified by an ISO/IEC 17025 accredited laboratory, with the full panel (cannabinoids, microbials, pesticides, heavy metals, water activity) that the EU-GMP site will re-test against.
- Sequence the permits. The Polish importer applies to GIF for the shipment-specific import permit, then you apply to Health Canada for the matching export permit. Both are tied to the International Narcotics Control Board (INCB) estimates each country files, so shipment quantities must fit within Poland's annual estimate for the year.
Budget six to nine months for a first shipment when your Polish partner already holds an authorisation, and longer if a new URPL filing is required. Lead times compress considerably on repeat shipments once the documentation set is established.
Market signals importers and LPs should read
Poland is worth the paperwork because the demand is real and measurable. Cannabis Europa's 2026 legal review puts the active patient base above 105,000 at the end of 2025, and industry estimates cited by Polish pharmacy sources place it well above that in 2026. Pharmacy-level pricing sat between roughly 12.80 and 13.80 euros per gram in early 2026 across about 30 authorised flower products.
The market also carries a lesson in regulatory risk. From 7 November 2024, Polish physicians have been required to examine a patient in person before prescribing controlled substances, cannabis included. Monthly prescriptions fell by more than half within weeks, from around 68,000 in October 2024 to about 28,000 by December.
Clinics then rebuilt on in-person and hybrid models, and by December 2025 monthly dispensing had passed the pre-restriction peak. If you're modelling Polish volumes, build in that kind of policy shock rather than assuming linear growth.
Three signals matter most for a Canadian LP entering now:
- Potency demand is moving up. New cultivars launched into Poland by Canadian producers in spring 2026 were positioned at 27 to 29 percent THC. High-THC indoor flower with a consistent terpene profile is what Polish wholesalers are actively sourcing.
- Portuguese supply dominates on price. With two-thirds of volume originating in Portugal, Canadian flower competes on quality tier, not on landed cost. Machine-trimmed commodity flower struggles here.
- Supply chain reliability is scarce. Early years of the programme saw shortages driven by slow authorisations and permits. Wholesalers now reward suppliers who can commit to a shipment cadence and hit it. Your EU-GMP partner's capacity and your own Good Distribution Practice chain are part of the pitch.
Common mistakes when supplying Poland
The failure points we see are rarely about the flower. They're about assuming Poland works like Germany or Australia.
The first mistake is treating the URPL authorisation as the importer's problem. It names your product, so any change to cultivar, potency range, or manufacturing site can put a batch outside the authorised specification. Agree in the supply contract who owns variations and how long they take.
The second is shipping before the German (or other EU) release site has confirmed it can release into Poland specifically. An EU-GMP certificate covers manufacturing quality. It doesn't by itself grant the right to place product on the Polish market. The wholesale and narcotics authorisations in Poland sit with your Polish partner, and the release site needs to be named in that chain.
The third is under-documenting. Polish pharmacies compound each prescription from your flower, so the certificate of analysis travels further down the chain than in most markets. A pharmacist in Kraków may read it.
Write it accordingly, and make sure the version the EU-GMP site issues matches the Canadian original batch for batch. Our Germany export requirements guide covers the documentation set that most Polish routes also depend on.
AlphaLeaf is a Montreal-based Health Canada Licensed Producer of indoor-grown, hand-trimmed cannabis flower with refined genetics and full batch traceability. We hold export authorisation under the Cannabis Act, test every batch through ISO/IEC 17025 accredited laboratories, and maintain the GACP and EU-GMP-aligned documentation that European release sites and Polish wholesalers require before a first shipment.
If you're a Polish wholesaler or a European release site evaluating Canadian supply for 2026 and 2027, contact AlphaLeaf to review cultivar availability, potency ranges, and shipment cadence.
Frequently Asked Questions
Can a Canadian LP export cannabis directly to Poland?
Yes, but only as EU-GMP released product. Since most Canadian sites are GACP-certified rather than EU-GMP certified, flower usually ships to an EU-GMP site in Germany or Portugal for testing, packaging, and Qualified Person release, then moves into Poland under the Polish importer's GIF permit. Each Canadian shipment needs its own Health Canada export permit under the Cannabis Regulations.
Who regulates medical cannabis imports in Poland?
Two bodies. The Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL) grants the five-year marketing authorisation for each cannabis raw material product. The Chief Pharmaceutical Inspectorate (GIF) licenses wholesalers, issues narcotics authorisations, and approves each import shipment.
How long does it take to get a Polish marketing authorisation for cannabis flower?
Prohibition Partners' 2025 review reports the URPL process typically takes up to two years. That is why most Canadian LPs enter Poland through a partner that already holds an authorisation their flower can be supplied under, rather than filing a new one.
Does Poland grow its own medical cannabis?
No commercial cultivation exists. Only research institutions can cultivate under a special GIF permit, and only one has received it. In practice the market is entirely import-supplied, with roughly two-thirds of flower originating in Portugal and about one-third in Canada as of early 2026.
How big is Poland's medical cannabis market in 2026?
Polish pharmacies dispensed about 5,450 kilograms of dried flower in 2025, up roughly 12 percent year over year, serving more than 105,000 active patients by year end. Pharmacy prices in early 2026 sat between roughly 12.80 and 13.80 euros per gram across about 30 authorised flower products.
Which AlphaLeaf products suit the Polish market?
Polish wholesalers are sourcing high-THC indoor flower with consistent terpene expression. AlphaLeaf's hand-trimmed, large-bud indoor cultivars, including Ice Cream Cake at 30.3 percent THC, are grown in Montreal and tested through ISO/IEC 17025 accredited laboratories, with the batch documentation an EU-GMP release site needs.
